ReveonAI showcases AI-assisted, expert-led solutions at PDA India 2026

6 August 2026 — ReveonAI, an AI-assisted, expert-led software company for pharma quality and manufacturing, exhibited at the PDA India Chapter 2026 Annual Meeting, held 3–5 August at the Hyderabad Convention Centre. The 4th PDA India Annual Meeting brought together QA, manufacturing, regulatory, and leadership professionals from across the pharmaceutical and biopharmaceutical industry.

Organized under the theme “Enhancing Quality Mindset Amid Changing Regulatory Expectations & Sustaining Supply Resilience — Beyond Inspection to Quality Excellence,” the program ran parallel tracks for pharma and biopharma across three focus areas: inspection readiness and regulatory responses, data integrity and quality culture, and risk-based approaches in sterile manufacturing. Each of these maps directly to the workflows ReveonAI's software supports.

At its booth, ReveonAI walked visitors through its GMP-native suite for pharma quality and manufacturing — InvestigationAssist, AuditSure, ResponseDraft, DocReview.AI, BatchReview+, and SOPComply+, each designed to compress the documentation load in deviations, audits, batch record review, and regulatory responses while keeping qualified experts in control of every decision. The AI reads, drafts, structures, and flags; a qualified human reviews and approves every output.

“Pharma quality teams tell us they want to move from prep-week scrambles to continuous inspection readiness, but they can't add headcount and won't compromise on control. That's exactly the problem our software was built to solve, the AI does the reading, drafting, and flagging, and the qualified human makes every call.”

“The theme this year (beyond inspection to quality excellence) is exactly the shift customers keep telling us they want. It stops being about surviving the next audit and starts being about running a quality system where inspection-readiness is the default state. AI can carry a lot of that documentation load, but only when it's built by people who have lived inside a GMP site.”

ReveonAI's participation continues a growing engagement with the PDA community. At the PDA Annual Conference India Chapter 2025, the company received recognition for its paper on integrating GenAI into deviation management, and it has since contributed as part of PDA's commenting team on the FDA Draft Guidance for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.

Teams that met ReveonAI in Hyderabad, or who could not, can request a working walkthrough of any product on one of their own quality workflows by writing to contact@reveonai.com.